Research
-
ABBV-295: Monthly Dosing Remains an Early Finding
AbbVie's new results support testing longer gaps between injections. The monthly group’s weight result was 7.9%, and the drug remains experimental.
-
CagriSema Food Noise: Fewer Cravings in a Trial
A 130-person trial reported fewer cravings and changed brain responses to food pictures. The scans add evidence, with limits that matter.
-
Counterfeit Ozempic Charges: What to Check Now
Federal charges describe an alleged counterfeit Ozempic distribution scheme. FDA’s pen warnings and a traceable pharmacy record explain what someone holding a pen can check.
-
Generic Wegovy: New Lawsuit, No U.S. Launch Date
Mylan's September 23 patent challenge sets no U.S. generic launch date. Here's what the filing changes for someone prescribed semaglutide.
-
Onswik: Weekly Insulin Needs Blood Sugar Checks
Onswik supplies background insulin once a week for adults with type 2 diabetes. Fewer shots still require blood sugar checks and a clear prescribing plan.
-
Orforglipron Heart Safety: Reassuring, With Limits
ACHIEVE-4 met its heart-safety standard against insulin glargine. The lower death rates are encouraging signals that need confirmation.
-
Sermorelin Allergic Reaction: What Reports Mean
New reporting describes severe reactions after peptide injections. Five accounts cannot establish a risk rate; breathing trouble or collapse means emergency care.
-
Retatrutide Type 2 Diabetes Results: Not Approved
TRIUMPH-2 reported up to 20.8% average weight loss over 80 weeks in adults with type 2 diabetes. Retatrutide is still being tested and has no approved product available.
-
Switching From Wegovy Injection to Pill: New Data
Today's OCTANE results found an average 4.1% weight loss three months after switching to the Wegovy pill. The selected group and short follow-up matter when reading that number.
-
Trevogrumab: Less Lean Mass Lost on Semaglutide
New COURAGE findings report less lean-tissue loss when trevogrumab is added to semaglutide. Muscle size, strength and long-term safety remain separate questions.
-
What Are Incretins? GIP and GLP-1, Explained
Incretins are the gut hormones that tell your pancreas a meal has arrived. There are two, GIP and GLP-1, and today's GLP-1 and dual-agonist medicines are built to copy them.
-
Zepbound vs Wegovy HD: The New Claims Have Limits
September's weight-loss and heart-risk headlines answer different questions. Neither puts Zepbound and Wegovy HD side by side in one trial.
-
PT-141 News Update: September 2026
The Vyleesi label didn't change this quarter. What did: FDA warning letters that named PT-141 sold online, a lab study on how the peptide breaks down, and a warning about its tanning-drug cousin.
-
Is Thymosin Alpha 1 FDA Approved? The Full Record
No thymosin alpha-1 product has ever been FDA-approved. Its U.S. record runs from four orphan designations to a 4–17 advisory vote in December 2024, and FDA has not yet written a rule.
-
NAD+ News Update: September 2026
Supplements kept raising blood NAD+ this quarter without moving memory, fatigue or sleep scores, and NAD+'s regulatory status stayed where it was. Here is every dated change, June through September.
-
TB-500 FDA Review: Where It Stands After the Vote
TB-500 has never had an FDA-approved product. Its review for a federal compounding list ran from a 2022 nomination to a July 2026 committee vote, and FDA has not acted on that vote yet.
-
What Is Off-Label Use? Meaning, Legality, Examples
Off-label use means prescribing an approved drug in a way its label doesn't describe. It's legal and common, and it isn't the same thing as a compounded or an unapproved drug.
-
NECC Meningitis Outbreak: What Changed After 2012
On September 26, 2012, a Massachusetts compounding pharmacy recalled three lots of steroid injections. The outbreak behind that recall killed 64 people by CDC's count and led Congress to create 503B outsourcing facilities.
-
MOTS-c News Update: September 2026
July's FDA advisory vote was the quarter's headline, but no rule has followed it. Here is what changed for MOTS-c from June to September, and what did not.
-
What Is a Boxed Warning? The Black Box, Explained
FDA calls it the most prominent safety warning a prescription label can carry. It marks a serious risk to weigh, not a ban, and the thyroid box on GLP-1 labels shows how to read one.
Page 5 of 8 · 160 articles